Myocardial Na,K-ATPase: The molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure

Cardiovascular Research

Volumn 55, Issue 4, 2002, Pages 710-713

  Kjeldsen, K ^a   Norgaard A ^b   Gheorghiade, M ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Heart failure; Hemodynamics; Ion pumps

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DIGITALIS GLYCOSIDE; DIGOXIN;

CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; ENZYME ANALYSIS; HEART FAILURE; HEMODYNAMICS; HUMAN; INOTROPISM; MOLECULAR BIOLOGY; MORTALITY; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; TREATMENT INDICATION;

AGED; CARDIOTONIC AGENTS; DIGOXIN; DIURETICS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MYOCARDIUM; NA(+)-K(+)-EXCHANGING ATPASE;

EID: 0036053571     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00466-2     Document Type: Review

References (37)

1. Chronic heart failure in the United States
2. The action of intravenous digoxin in man
3. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy. A hemodynamic-hormonal study
4. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure
5. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors
6. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial
7. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE study
8. The effect of digoxin on mortality and morbidity in patients with heart failure
9. ABC of heart failure. Management: Digoxin and other inotropes, beta blockers, and antiarrhythmic and antithrombotic treatment
10. Evaluating quality of care for patients with heart failure
11. Differences in drug treatment of chronic heart failure between European countries
12. Safety concerns about digoxin after acute myocardial infarction
13. Digoxin and mortality in chronic heart failure. UK heart investigation
14. Should we still prescribe digoxin in mild-to-moderate heart failure? Is quality of life the issue rater than quantity?
15. Health economic consequences of the pharmacological treatment of heart failure
16. The role of digitalis in the treatment of heart failure
17. Digitalis
18. The influence of some cations on an adenosine triphosphatase from peripheral nerves
19. The influence of some cations on an adenosine triphosphatase from peripheral nerves
20. Enzymatic basis for the active transport of Na and K across cell membrane
21. Digitalis. Mechanisms of action and clinical use
22. Clinical and therapeutic significance of the Na,K-pump
23. Identification of a specific role for the Na,K-ATPase alpha 2 isoform as a regulator of calcium in the heart
24. Isoform-specific regulation of the Na,K-pump in heart
25. Na,K-ATPase activity in a preparation from human post-mortem myocardium
26. No adaptation to digitalization as evaluated by digitalis receptor (Na,K-ATPase) quantification in explanted hearts from donors without heart disease and from digitalized recipients with end-stage heart failure
27. Relation of left ventricular function and Na,K-pump concentration in suspected idiopathic dilated cardiomyopathy
28. Myocardial adenine nucleotides, glycogen, and Na,K-ATPase in patients with idiopathic dilated cardiomyopathy requiring mechanical circulatory support
29. Na,K-ATPase expression in normal and failing human heart
30. Reduced sodium pump alpha 1, alpha 3, and beta1-isoform protein levels and Na,K-ATPase activity but unchanged Na-Ca exchanger protein levels in human heart failure
31. Inhibition of electrogenic Na-pumping attributable to binding of cardiac steroides to high-affinity pump sites in human atrium
32. Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na,K-pump
33. Angiotensin-converting enzyme inhibition, intracellular Na, and Na-K pumping in cardiac myocytes
34. Long-term digitalis therapy improves left ventricular function in heart failure
35. Therapeutic range of digoxin's efficacy in heart failure: What is the evidence?
36. Review of clinical experience with digoxin immune Fab (ovine)